Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01180036 · ClinicalTrials.gov registry record · Phase 2
MEmbranous Nephropathy Trial Of Rituximab
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
NCT01180036: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT01180036 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 130 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01180036, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
Study Summary
The primary outcome of this study is to determine whether or not the B cell targeting with Rituximab is non-inferior or more effective than Cyclosporine in inducing long term remission of proteinuria.
Interventions
- DRUG Rituximab
- DRUG Cyclosporine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2011-11 |
| Est. Completion | 2017-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01180036
The ClinicalTrials.gov registry entry for NCT01180036 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT01180036 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01180036 about?
NCT01180036 is a clinical study titled "MEmbranous Nephropathy Trial Of Rituximab". The primary outcome of this study is to determine whether or not the B cell targeting with Rituximab is non-inferior or more effective than Cyclosporine in inducing long term remission of proteinuria.
What is the current status of trial NCT01180036?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2011-11. Estimated completion is 2017-10-01.
What interventions are being tested in trial NCT01180036?
The interventions under investigation include: Rituximab (DRUG), Cyclosporine (DRUG).
Who is sponsoring clinical trial NCT01180036?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.